What are the effects of evantumumab on the liver?

Amivantamab (Amivantamab) is an anti-EGFR (epidermal growth factor receptor) and MET (hepatocyte growth factor receptor) dual inhibitory monoclonal antibody. It is mainly used to treat advanced or metastatic non-small cell lung cancer (NSCLC). It reduces the growth and proliferation of cancer cells by inhibiting the activation of EGFR and MET. During treatment, evantumumab may have some effects on the liver, especially abnormal liver function.

Although evantumumab, a targeted therapy, has less of an impact on the liver than traditional chemotherapy drugs, studies have shown that it may cause abnormal liver function in some patients. Common liver side effects include increased liver enzyme levels (such as ALT, AST, etc.). These liver enzyme elevations are usually reversible, and most patients return to normal after discontinuation of medication. However, in some cases, elevated liver enzymes may be an early sign of treatment, indicating that the patient's liver may have suffered some damage.

Because evantumumab may cause abnormal liver function, doctors usually recommend that patients undergo regular liver function monitoring during treatment, including checking liver enzyme levels in the blood. This helps to detect any potential liver problems promptly and allow for appropriate intervention. If a patient develops severe liver damage during treatment, the doctor may consider adjusting the drug dose or temporarily stopping treatment until liver function recovers.

Although evantumumab is less hepatotoxic, individual patient differences may affect hepatic tolerability. For example, patients with pre-existing liver disease (such as cirrhosis, hepatitis B or C infection, etc.) may face a higher liver burden when taking evantumumab. Therefore, before starting treatment, doctors will evaluate the patient's liver health and develop an individualized treatment plan based on the patient's specific situation.

Overall, evantumumab has a limited effect on the liver, but it may still cause mild to moderate liver function abnormalities. To ensure the safety of treatment, patients need to have their liver function checked regularly during treatment. If there are signs such as elevated liver enzymes, you should report it to your doctor in time and make adjustments according to your doctor's instructions.

Reference materials:https://www.rybrevant.com/